Stoke therapeutics, inc. (STOK)

CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19
Cash flows from operating activities:
Net loss

-37,622

-32,325

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

563

450

0

0

0

Stock-based compensation

2,495

1,922

0

0

0

Loss on disposal of property and equipment

-3

-3

0

0

0

Reduction in the carrying amount of right of use assets

0

-

-

-

-

Changes in assets and liabilities:
Prepaid expenses and other current assets

2,152

2,024

0

0

0

Accounts payable and accrued liabilities

1,145

891

0

0

0

Deferred rent

-

28

0

0

0

Net cash used in operating activities

-35,294

-31,055

0

0

0

Cash flows from investing activities:
Purchases of property and equipment

2,153

1,635

0

0

0

Proceeds from sale of property and equipment

-

1

0

0

0

Net cash used in investing activities

-2,154

-1,634

0

0

0

Cash flows from financing activities:
Payments on capital lease

0

-

-

-

0

Proceeds from issuance of common stock upon exercise of stock options

440

315

0

0

0

Deferred Financing Costs

-

-

-

-

0

Net cash provided by (used in) financing activities

150,028

149,762

0

0

0

Net decrease in cash, cash equivalents and restricted cash

112,580

117,073

0

0

0

Supplemental Disclosure of Non-Cash Investing and Financing Activities:
Property and equipment included in accrued expense and accounts payable

0

-

-

0

0

Right-of-use assets recognized in exchange for operating leases upon adoption of Topic 842

0

-

-

-

-

Deferred offering costs not yet paid

-

-

-

0

0